Visual Abstracts: The New England Journal of Medicine
Browse Visual Abstracts from the New England Journal of Medicine.
Related Articles
Obicetrapib in Patients at High Cardiovascular Risk | NEJM
Quick Take Video Summary from The New England Journal of Medicine — Obicetrapib in Patients at High Cardiovascular Risk
Obicetrapib in Patients at High Cardiovascular Risk | NEJM
Quick Take Video Summary from The New England Journal of Medicine — Obicetrapib in Patients at High Cardiovascular Risk
Lifesaving Diagnosis through Prenatal Genomic Sequencing | NEJM
Prenatal genomic sequencing revealed congenital thrombotic thrombocytopenic purpura, enabling immediate plasma therapy. The case highlights the value and ethical complexity of reporting incidental …
Retropubic Prostatectomy | NEJM
UNTIL recently time and experience had accepted as satisfactory three principal operative approaches to the prostate: perineal prostatectomy, suprapubic transvesical prostatectomy and transurethral…
Self-Neglect in Older People — A Clinical, Social, and Ethical Dilemma | NEJM
Navigating cases of potential self-neglect is complicated for older adults and for the family members, clinicians, and social and legal services professionals involved in ensuring…
Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis | NEJM
A 57-year-old man presented with a 2-week history of worsening shortness of breath. Radiography and CT showed perihilar airspace opacities in both lungs, and bloody…
Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes | NEJM
Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We…
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity | NEJM
Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results…
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity | NEJM
Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | NEJM
Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy…